Diabetes, Metabolic Syndrome and Obesity (Sep 2019)
Ascophyllum Nodosum, Fucus Vesiculosus and chromium picolinate nutraceutical composition can help to treat type 2 diabetic patients
Abstract
Giuseppe Derosa,1–3 Maria Divina Pascuzzo,4 Angela D’Angelo,1,2 Pamela Maffioli1 1Centre of Diabetes and Metabolic Diseases, Department of Internal Medicine and Therapeutics, University of Pavia and Fondazione IRCCS Policlinico San Matteo, Pavia, Italy; 2Laboratory of Molecular Medicine, University of Pavia, Pavia, Italy; 3Center for Prevention, Surveillance, Diagnosis and Treatment of Rare Diseases, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy; 4Ambulatory Center ASL Torino 4 and ASL Città Di Torino, Torino, ItalyCorrespondence: Giuseppe DerosaDepartment of Internal Medicine and Therapeutics, University of Pavia, and Fondazione IRCCS Policlinico San Matteo, P.le C. Golgi, 2, Pavia 27100, ItalyTel +39 038 252 6217Fax +39 038 252 6259Email [email protected]: To evaluate the actions of a combination of polifenolic composition (extracted from Ascophyllum Nodosum and Fucus Vesiculosus, InSea2®) and chromium picolinate compared to placebo in addition to previously taken anti-diabetic therapy in patients with type 2 diabetes.Methods: 175 Caucasian patients with type 2 diabetes were randomized to take nutraceutical combination or placebo for 6 months. One hundred and sixty-four cases completed the study. At baseline and after 6 months, glyco-metabolic control and lipid profile were evaluated.Results: Glycated hemoglobin was significantly reduced by the nutraceutical combination, but not by placebo, both compared to baseline (p<0.05), and compared to placebo (p<0.05). A similar trend was recorded for fasting plasma glucose (FPG) [−23.5% (p<0.01) vs baseline, and −18.0% (p<0.01) vs placebo] and post-prandial glucose (PPG) [−17.1% (p<0.01) vs baseline, and −11.1% (p<0.05) vs placebo]. No variations of lipid profile were recorded compared to baseline, even if it seems to observe a reduction trend of triglycerides level in the nutraceutical group.Conclusion: In conclusion, a nutraceutical combination of polifenolic composition and chromium picolinate in addition to previously taken anti-diabetic therapy can be helpful in reducing glycated hemoglobin in patients with type 2 diabetes mellitus.Keywords: Ascophyllum Nodosum, chromium, Fucus Vesiculosus, glycemic control
